• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SAPIEN 3 假体经股动脉主动脉瓣置换术后住院时间评估:一项法国多中心前瞻性观察性试验。

Evaluation of length of stay after transfemoral transcatheter aortic valve implantation with SAPIEN 3 prosthesis: A French multicentre prospective observational trial.

机构信息

Normandie University, UNIROUEN, INSERM U1096, Department of Cardiology, Rouen University Hospital, FHU REMOD-VHF, 76000 Rouen, France.

Rennes University, CHU de Rennes, INSERM LTSI U1099, 35000 Rennes, France.

出版信息

Arch Cardiovasc Dis. 2020 Jun-Jul;113(6-7):391-400. doi: 10.1016/j.acvd.2019.11.010. Epub 2020 May 14.

DOI:10.1016/j.acvd.2019.11.010
PMID:32418883
Abstract

BACKGROUND

Complications decrease after transfemoral transcatheter aortic valve implantation (TAVI), and early discharge is feasible and safe in selected populations.

AIMS

To evaluate length of stay (LOS) and reasons for prolonged hospitalisation after transfemoral TAVI in unselected patients.

METHODS

Patients with severe aortic stenosis, who had transfemoral TAVI with the SAPIEN 3 prosthesis using exclusively local anaesthesia, were prospectively and consecutively included at five French high-volume centres. LOS was calculated from TAVI procedure to discharge. Reasons for prolonged hospitalisation (i.e.>3 days) were evaluated.

RESULTS

Between 2017 and 2018, 293 patients were included, with a mean age of 82.4±6.5 years and a mean logistic EuroSCORE of 13.7±9.0%. The in-hospital mortality rate was 1.4%. The median LOS was 5 (3-7) days, and varied considerably between centres (from 2 to 7 days). Sixty-four (21.8%) patients were discharged within 3 days after transfemoral TAVI. Reported reasons for prolonged hospitalisation were complications in 62.2%, loss of autonomy in 3.1%, discharge refusal in 2.2% and logistical reasons in 0.9%. In 31.6% of cases, the investigators reported no apparent reasons.

CONCLUSIONS

The results of our study suggest that LOS after transfemoral TAVI, using the SAPIEN 3 prosthesis and a minimalist approach, varies considerably between centres. In almost a third of cases, hospitalisation was prolonged without any apparent reason. Efforts should be made to educate centres to reduce LOS.

摘要

背景

经股动脉经导管主动脉瓣置换术(TAVI)后并发症减少,在选定的人群中,早期出院是可行且安全的。

目的

评估经股动脉 TAVI 后未选择患者的住院时间(LOS)和延长住院时间的原因。

方法

前瞻性连续纳入 2017 年至 2018 年在法国五家高容量中心接受经股动脉 TAVI 并单独使用局部麻醉的 SAPIEN 3 假体治疗的严重主动脉瓣狭窄患者。LOS 从 TAVI 手术到出院计算。评估延长住院时间(即>3 天)的原因。

结果

共纳入 293 例患者,平均年龄为 82.4±6.5 岁,平均逻辑 EuroSCORE 为 13.7±9.0%。院内死亡率为 1.4%。中位 LOS 为 5(3-7)天,且各中心之间差异较大(2-7 天)。64(21.8%)例患者在经股动脉 TAVI 后 3 天内出院。延长住院时间的报告原因包括并发症 62.2%、自理能力丧失 3.1%、拒绝出院 2.2%和后勤原因 0.9%。在 31.6%的情况下,研究者报告没有明显的原因。

结论

我们的研究结果表明,使用 SAPIEN 3 假体和极简主义方法进行经股动脉 TAVI 后,各中心之间的 LOS 差异很大。将近三分之一的情况下,住院时间延长而没有明显原因。应努力教育中心以缩短 LOS。

相似文献

1
Evaluation of length of stay after transfemoral transcatheter aortic valve implantation with SAPIEN 3 prosthesis: A French multicentre prospective observational trial.SAPIEN 3 假体经股动脉主动脉瓣置换术后住院时间评估:一项法国多中心前瞻性观察性试验。
Arch Cardiovasc Dis. 2020 Jun-Jul;113(6-7):391-400. doi: 10.1016/j.acvd.2019.11.010. Epub 2020 May 14.
2
Transfemoral aortic valve implantation is more successful with the Edwards Sapien 3 compared with the Edwards XT for the treatment of symptomatic severe aortic stenosis.经股主动脉瓣置换术治疗症状性重度主动脉瓣狭窄时,爱德华兹·萨皮恩 3 号瓣比爱德华兹 XT 瓣更成功。
Arch Cardiovasc Dis. 2018 Aug-Sep;111(8-9):470-479. doi: 10.1016/j.acvd.2017.05.012. Epub 2017 Nov 8.
3
Transfemoral aortic valve implantation with new-generation devices: the repositionable Lotus vs. the balloon-expandable Edwards Sapien 3 valve.经股主动脉瓣置换术:可重定位的 Lotus 瓣膜与球囊扩张式 Edwards Sapien 3 瓣膜比较。
J Cardiovasc Med (Hagerstown). 2018 Nov;19(11):655-663. doi: 10.2459/JCM.0000000000000705.
4
Comparison of clinical outcomes after transcarotid and transsubclavian versus transfemoral transcatheter aortic valve implantation: A propensity-matched analysis.经颈动脉与锁骨下动脉入路和经股动脉入路行经导管主动脉瓣植入术后临床结局的比较:倾向评分匹配分析。
Arch Cardiovasc Dis. 2020 Mar;113(3):189-198. doi: 10.1016/j.acvd.2020.01.001. Epub 2020 Feb 6.
5
Transcutaneous aortic valve implantation using the carotid artery access: Feasibility and clinical outcomes.经颈动脉途径行经皮主动脉瓣植入术:可行性及临床结果。
Arch Cardiovasc Dis. 2017 Jun-Jul;110(6-7):389-394. doi: 10.1016/j.acvd.2016.10.005. Epub 2017 Apr 19.
6
Predictability and Outcome of Vascular Complications after Transfemoral Transcatheter Aortic Valve Implantation.经股动脉导管主动脉瓣植入术后血管并发症的可预测性及结局
J Heart Valve Dis. 2016 Mar;25(2):173-181.
7
Transcarotid Approach for Transcatheter Aortic Valve Replacement With the Sapien 3 Prosthesis: A Multicenter French Registry.经颈动脉途径行经导管主动脉瓣置换术联合使用 Sapien 3 瓣膜:一项多中心法国注册研究。
JACC Cardiovasc Interv. 2019 Mar 11;12(5):413-419. doi: 10.1016/j.jcin.2018.11.014. Epub 2019 Feb 13.
8
Five-Year Outcomes of Transfemoral Transcatheter Aortic Valve Replacement or Surgical Aortic Valve Replacement in a Real World Population.真实世界人群中行经股动脉的经导管主动脉瓣置换术与外科主动脉瓣置换术的 5 年结果。
Circ Cardiovasc Interv. 2019 Jul;12(7):e007825. doi: 10.1161/CIRCINTERVENTIONS.119.007825. Epub 2019 Jul 9.
9
A feasibility study of transaxillary TAVI with the lotus valve.经腋入路应用莲花瓣主动脉瓣输送系统行 TAVI 的可行性研究
Catheter Cardiovasc Interv. 2018 Sep 1;92(3):542-549. doi: 10.1002/ccd.27409. Epub 2017 Nov 11.
10
Analysis of length of stay after transfemoral transcatheter aortic valve replacement: results from the FRANCE TAVI registry.经股动脉主动脉瓣置换术后住院时间分析:来自 FRANCE TAVI 注册研究的结果。
Clin Res Cardiol. 2021 Jan;110(1):40-49. doi: 10.1007/s00392-020-01647-4. Epub 2020 Apr 25.

引用本文的文献

1
Reducing Length of Hospital Stay Following Transcatheter Aortic Valve Implantation.经导管主动脉瓣植入术后缩短住院时间
J Clin Med. 2024 Sep 13;13(18):5433. doi: 10.3390/jcm13185433.
2
Patient with heart failure: importance to treat valvular diseases.心力衰竭患者:治疗瓣膜疾病的重要性。
Eur Heart J Suppl. 2020 Dec 23;22(Suppl Pt t):P38-P41. doi: 10.1093/eurheartj/suaa184. eCollection 2020 Dec.